SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending amid concerns about the cost of capital related to a large senior secured notes offering, with community members debating its potential impact and investor appetite. Some traders speculate about an upcoming short squeeze due to the high short interest, while others discuss institutional hedging strategies involving long positions and put options. Despite recent price declines, long-term bulls cite significant AI infrastructure contracts and partnerships, urging patience and viewing the dip as a buying opportunity.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending as the stock hits all-time lows, triggering strong reactions from both bulls and bears. The community is actively debating whether the stock is a buying opportunity or a value trap, with some citing upcoming earnings as a potential catalyst. Discussions also include the impact of a recent partnership and broader market conditions on the stock's performance.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss the potential for government funding and the significance of Gerard Barron's trip to DC, alongside commentary on permit timelines. The stock's confidence-inspiring earnings call and the vessel's upcoming work in Japan are also key talking points, though some express concerns about market manipulation and the government shutdown's impact.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors await a decision from the European Medicines Agency (EMA) regarding its Alzheimer's drug, Blarcamesine; the community is split, with some anticipating approval based on the drug's potential and safety profile, while others express concern over trial data and the influence of negative opinions from figures like Martin Shkreli. Discussions also include short squeeze potential, stock manipulation accusations, and comparisons to other Alzheimer's drugs.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

RCAT is trending due to concerns about reduced guidance for 2025 and disappointing earnings, leading to discussions about management credibility and the impact of government shutdowns on contracts. The community is comparing RCAT's performance to competitors like ONDS, with some expressing frustration over missed promises and potential buying opportunities at lower prices. Sentiment is mixed, with long-term bulls remaining hopeful despite recent struggles.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Round Rock, TX.

TSS Inc

TSSI is trending due to recent earnings results that spurred a significant sell-off, with the community debating the company's future prospects and management's communication. Discussions revolve around the impact of facility upgrades, government shutdowns, and the strength of the Dell partnership on TSSI's performance. Some investors see this as a buying opportunity, while others express concerns about the company's execution and transparency.

Applied Materials, Inc. provides manufacturing equipment, services and software to the semiconductor, display and related industries. It operates through the following segments: Semiconductor Systems, Applied Global Services, and Display. The Semiconductor Systems segment includes semiconductor capital equipment for etch, rapid thermal processing, deposition, chemical mechanical planarization, metrology and inspection, wafer packaging, and ion implantation. The Applied Global Services segment provides solutions to optimize equipment, performance, and productivity. The Display segment offers products for manufacturing liquid crystal displays, organic light-emitting diodes, equipment upgrades, and other display technologies for TVs, monitors, laptops, personal computers, smart phones, and other consumer-oriented devices. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is trending downwards following its earnings report, with concerns arising from weaker-than-expected guidance and a significant revenue impact due to new export restrictions, particularly affecting business in China. Community discussion revolves around the severity of the issues and whether the dip represents a buying opportunity or a sign of deeper challenges for the company and the semiconductor equipment sector. Some analysts highlight long-term growth potential, while others point to near-term headwinds and market share losses.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as a Bitcoin-native memecoin with a focus on community and a fair launch, contrasting it with other memecoins. Talk centers on potential exchange listings, its connection to Bitcoin's fundamentals, and the strength of its community, the #dogarmy.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros ($OMER) is trending as investors await potential FDA approval for Narsoplimab (NARSO) for TA-TMA by the end of December, with specific focus on the commencement of labeling discussions, a key indicator of progress; some express concern over potential review delays and the impact of the government shutdown. The community is weighing the implications of recent leadership changes at the FDA, with opinions divided over how it might affect OMER's prospects, while also monitoring the progress of the Novo Nordisk deal and potential buy out.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in George Town, Cayman Islands.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings ($NU) is trending as investors react to recent earnings and growth metrics, with community members debating whether the subdued market reaction reflects the stock's true potential.  Bullish sentiment centers on the company's impressive customer growth and profitability in Latin America, while bears express concerns about sideways trading and the stock's historical difficulty in breaking resistance levels. Discussions also include potential catalysts, such as expansion into the U.S. market and partnerships with companies like Amazon and OpenAI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Shares surged 141% to $6.41, marking their highest level since February 2024, after Minerva secured up to $200 million in financing led by top healthcare investors.</li><li>The FDA cleared the design for a confirmatory Phase 3 trial of roluperidone, a potential treatment for the negative symptoms of schizophrenia.</li><li>Retail traders on Stocktwits turned “extremely bullish,” citing the new funding and FDA alignment as signs of confidence in an eventual approval.</li></ul>Minerva Neurosciences' stock jumped to a nearly two-year high on Tuesday after the biotech firm announced a new financing deal that could bring in up to $200 million and outlined a clear regulatory path with the U.S. FDA for its lead schizophrenia drug, roluperidone.The company’s shares&nbsp;soared 141% to $6.41 on Tuesday, hitting their highest level since February 2024, before slipping 6.4% in after-hours trading.<h2 class="st-heading-2">Funding For Phase 3 Trial And NDA Resubmission</h2>Minerva said it raised $80 million upfront through a private financing round backed by leading healthcare investors, including Vivo Capital, Janus Henderson Investors, and Federated Hermes Kaufmann Funds.&nbsp;The deal could bring in as much as $200 million in total, with another $80 million tied to the exercise of Tranche A warrants and an additional $40 million linked to future clinical milestones under Tranche B warrants. Each preferred share was priced at $1,000, convertible into common stock at $2.11 pending shareholder approval.The firm said the investment would fully fund its planned confirmatory Phase 3 study of roluperidone, and NDA resubmission to the FDA. It will also be used to make preparations for a potential U.S. commercial launch, should the product gain approval.<h2 class="st-heading-2">Strengthening The Team</h2>Under the agreement, Minerva will increase the number of its directors to include up to three new members with significant experience in schizophrenia and drug development. The company also plans to establish a Scientific Advisory Board to help guide the Phase 3 study.“We will now refocus all of our efforts on the successful execution of the confirmatory trial with the objective of demonstrating that roluperidone can effectively treat patients with impairing negative symptoms,” CEO Remy Luthringer said in a statement.<h2 class="st-heading-2">FDA Agrees On Clear Trial Design</h2>The FDA has agreed on the design of the confirmatory Phase 3 study, which will test roluperidone 64 mg as a standalone treatment in patients with schizophrenia who suffer from negative symptoms such as lack of motivation, social withdrawal, and diminished emotional expression. The main goal of the trial will be to measure improvements in the PANSS Marder Negative Symptoms Factor Score after 12 weeks.The FDA has also asked Minerva to observe patients for up to 52 weeks to monitor relapse rates, helping to build evidence for roluperidone as a monotherapy. The company expects around 25%–30% of trial participants to be enrolled from U.S. sites.<h2 class="st-heading-2">Stocktwits Traders Eye FDA Milestone Upside</h2>On Stocktwits, retail sentiment for Minerva was ‘extremely bullish’ amid a 102,300% surge in 24-hour message volume.One user said they expected Minerva’s stock to climb sharply if it breaks past the $7 level, while another pointed to the company’s $200 million financing as a sign of confidence, suggesting that such investment likely reflects optimism around eventual FDA approval.<stembedurl>https://stocktwits.com/24cmKarMadhfromPrishtina/message/633140308</stembedurl><stembedurl>https://stocktwits.com/Myway1000/message/633126607</stembedurl><a href="https://stocktwits.com/symbol/NERV">Minerva’s stock</a> has nearly tripled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Minerva Neurosciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst

Shares surged 141% to $6.41, marking their highest level since February 2024, after Minerva secured up to $200 million in financing led by top healthcare investors.

Equity

Minerva Neurosciences, Inc. (NASDAQ:NERV) Sees Significant Decline in Short Interest

Minerva Neurosciences, Inc. (NASDAQ:NERV  Get Free Report) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 38,300 shares...

Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Minerva Neurosciences (NASDAQ:NERV) Cut to "Sell" at StockNews.com

StockNews.com downgraded shares of Minerva Neurosciences (NASDAQ:NERV  Free Report) from a hold rating to a sell rating in a research note published on Friday. Minerva Neurosciences Trading...

Minerva Neurosciences: Q4 Earnings Insights

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Minerva Neurosciences (NASDAQ:NERV) Raised to Hold at StockNews.com

StockNews.com upgraded shares of Minerva Neurosciences (NASDAQ:NERV  Free Report) from a sell rating to a hold rating in a research note released on Monday. Minerva Neurosciences Stock...

Minerva Neurosciences (NASDAQ:NERV) Cut to Sell at StockNews.com

StockNews.com lowered shares of Minerva Neurosciences (NASDAQ:NERV  Free Report) from a hold rating to a sell rating in a research note issued to investors on Friday. Minerva Neurosciences...

Minerva Neurosciences (NASDAQ:NERV) Stock Rating Lowered by StockNews.com

Minerva Neurosciences (NASDAQ:NERV  Get Free Report) was downgraded by equities researchers at StockNews.com from a hold rating to a sell rating in a research...

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

$IONQ

$RGTI

$QBTS

$QUBT

Are you buying the dip on any of these quantum stocks? 
 
If no, drop a comment.

NERV
Minerva Neurosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NERV News

NERVMinerva Neurosciences Inc